401P - MEK inhibitor retinopathy

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Complications of Treatment
Presenter Tamara Shukair
Citation Annals of Oncology (2017) 28 (suppl_5): v122-v141. 10.1093/annonc/mdx367
Authors T. Shukair
  • Ophthalmology, hospital madrid norte sanchinarro, 28050 - Madrid/ES

Abstract

Background

To evaluate the presence and characteristics of subretinal fluid (SRF) associated with the use of MEK inhibitors in the treatment of systemic cancer MEK retinopathy is described as symmetrical bilateral disease that develops in a time-dependent and dose-dependent manner.

Methods

In this prospective, observational study, collected data from 14 patients with locally advanced or metastatic cancer undergoing treatment with the MEK inhibitor as clinical trials between 2010-2013. They underwent regular ophthalmological examinations including determination of visual function, biomicroscopy, dilated fundoscopy and optical coherence tomography (OCT).

Results

Of the 14 participants, 10 (71%) were men; the mean (SD) age was 65 years (range, 41-80 years). Six (48%) study participants developed SRF during the study period. OCT revealed subfoveal neuroretinal elevation, serous retinal detachments often asymptomatic. In general it solves spontaneously without any apparent functional deficits or changes in structural integrity, and does not require the suspension of the treatment.

Conclusions

The presence of serous retinal detachment in patients undergoing treatment with the MEK inhibitor is common. Visual symptoms were mild and mainly transient and the presence of SRF did not lead to permanent ocular disorder. It is important to investigate all previous ocular disorders and pharmacologic interactions of MEK inhibitor that could associate with ocular effects.

Clinical trial identification

Legal entity responsible for the study

START Madrid

Funding

None

Disclosure

All authors have declared no conflicts of interest.